Drug discovery startup ArrePath introduced Thursday it has raised $20 million in a seed funding spherical led by the Boehringer Ingelheim Enterprise Fund, Perception Companions and Innospark Ventures.
Different members within the spherical embrace Viva BioInnovator, Arimed Capital, PTX Capital and Nor’easter Ventures. The corporate, which focuses on creating new sorts of anti-infective medication to greatest antimicrobial resistance, plans to make use of the funding to assist its machine learning-based drug discovery platform.
ArrePath additionally appointed Dr. Lloyd Payne as president and CEO. Payne most just lately served as govt vp, head of anti-infectives, at German drug discovery firm Evotec.
“This financing is a powerful vote of confidence, by a worldwide funding syndicate, in our platform and its huge potential in anti-infective drug discovery,” Payne mentioned in an announcement. “The funding will allow the development of our preliminary leads and enlargement of our discovery efforts, in addition to the enhancement of our imaging platform and the applying of machine studying within the discovery of recent medication to deal with important international well being challenges.”
Rupa Well being, which provides a platform the place suppliers can order a wide range of lab assessments and obtain outcomes, scored $20 million in Sequence A funding.
The spherical was led by Bessemer Ventures with participation from current traders together with First Spherical Capital, Lachy Groom, SV Angel, Floodgate, Hustle Fund, Operator Collective, the Chainsmokers, Jared Leto and Joe Montana.
In a publish on the corporate’s web site, CEO and cofounder Tara Viswanathan mentioned the platform permits suppliers to order conventional labs alongside different assessments developed by impartial firms, like microbiome analyses, which can be harder to entry.
CancerIQ introduced it had raised $14 million in a Sequence B funding spherical led by Merck International Well being Innovation Fund and Amgen Ventures. Different members embrace McKesson Ventures, OSF Ventures and HealthX Ventures.
The startup’s platform is embedded in an EHR and helps suppliers decide a person affected person’s most cancers danger based mostly on household historical past, genetics, well being behaviors and different components. It could additionally ship sufferers down totally different care pathways relying on outcomes, like screenings, vaccinations and way of life adjustments.
CancerIQ scored $4.8 million in Sequence A financing in 2020.
“CancerIQ’s imaginative and prescient is to finish most cancers as we all know it by eliminating well being disparities and democratizing entry to the most recent advances in most cancers early detection and prevention,” cofounder and CEO Feyi Olopade Ayodele mentioned in an announcement.
“We began by making genetic testing extra accessible and connecting sufferers to the best preventive providers on the proper time. This newest spherical of funding will assist CancerIQ attain extra sufferers and hook up with extra improvements that promise to rework most cancers from an endemic to a manageable situation.”
The spherical was led by Lightspeed Enterprise Companions, with participation from Maven Ventures and particular person traders. The spherical comes a couple of yr after the corporate introduced a $1.8 million seed spherical.
Dawn plans to make use of the funding to develop throughout the nation and concentrate on well being fairness.
juli, an AI-enabled app that tracks metrics like exercise, sleep, lab outcomes, EHR information and climate to assist customers handle persistent situations, raised $3.8 million in seed funding.
The spherical was led by Speedinvest and Norrsken VC, with participation from SoftBank’s Imaginative and prescient Fund Emerge Program and Dieter von Holtzbrinck Ventures.
“juli helps sufferers, suppliers and employers determine behavioral triggers that worsen or enhance essentially the most hard-to-treat and sophisticated persistent situations, together with bronchial asthma, migraines, melancholy and bipolar dysfunction,” CEO and cofounder Bettina Hein mentioned in an announcement. “With the assist of Speedinvest, Norrsken and our different traders, we will develop our attain to enhance affected person well being and decrease healthcare prices.”